Martin Van Royen

Dr. Martin Van Royen

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Bioengineering
Verified
Journal Article
Open access
PDF file
THThomas A. Hartjes
Thomas A. Hartjes
SMSerhii Mytnyk
Serhii Mytnyk
GJGuido Jenster
Guido Jenster
VSVolkert van Steijn
Volkert van Steijn
MRMartin Van Royen
Martin Van Royen
Extracellular vesicles (EVs) are a family of small membrane vesicles that carry information about cells by which they are secreted. Growing interest in the role of EVs in intercellular communication, but also in using their diagnostic, prognostic and therapeutic potential in (bio) medical applications, demands for accurate assessment of their biochemical and physical properties. In this review, we provide an overview of available technologies for EV analysis by describing their working principles, assessing their utility in EV research and summarising their potential and limitations. To emphasise the innovations in EV analysis, we also highlight the unique possibilities of emerging technologies with high potential for further development.

18 October 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LZLuca M. Zaeck
Luca M. Zaeck
MLMart M. Lamers
Mart M. Lamers
BVBabs E Verstrepen
Babs E Verstrepen
TBTheo M. Bestebroer
Theo M. Bestebroer
MRMartin Van Royen
Martin Van Royen
Rory de VriesRory de Vries
Rory de Vries
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara—Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an MVA-based influenza vaccine leads to lower MPXV-neutralizing antibody levels, whereas a third vaccination with the same MVA-based vaccine significantly boosts the antibody response. As the role of MPXV-neutralizing antibodies as a correlate of protection against disease and transmissibility is currently unclear, we conclude that cohort studies following vaccinated individuals are necessary to assess vaccine efficacy in at-risk populations.

1 December 2013 in European Journal of Cancer
Verified
Journal Article
Closed access
RSR.J. van Soest
R.J. van Soest
MRMartin Van Royen
Martin Van Royen
EME.S. de Morrée
E.S. de Morrée
JMJ.M. Moll
J.M. Moll
WTW. Teubel
W. Teubel
WWW.M. van Weerden
W.M. van Weerden

6 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMarta Nadal
Marta Nadal
Stefan PrekovicStefan Prekovic
Stefan Prekovic
NGNerea Gallastegui
Nerea Gallastegui
CHChristine Helsen
Christine Helsen
MAMontserrat Abella
Montserrat Abella
Eva Estebanez-PerpinaEva Estebanez-Perpina
Eva Estebanez-Perpina
The androgen receptor (AR) plays a crucial role in normal physiology, development and metabolism as well as in the aetiology and treatment of diverse pathologies such as androgen insensitivity syndromes (AIS), male infertility and prostate cancer (PCa). Here we show that dimerization of AR ligand-binding domain (LBD) is induced by receptor agonists but not by antagonists. The 2.15-Å crystal structure of homodimeric, agonist- and coactivator peptide-bound AR-LBD unveils a 1,000-Å2 large dimerization surface, which harbours over 40 previously unexplained AIS- and PCa-associated point mutations. An AIS mutation in the self-association interface (P767A) disrupts dimer formation in vivo, and has a detrimental effect on the transactivating properties of full-length AR, despite retained hormone-binding capacity. The conservation of essential residues suggests that the unveiled dimerization mechanism might be shared by other nuclear receptors. Our work defines AR-LBD homodimerization as an essential step in the proper functioning of this important transcription factor.

14 February 2019 in Cancer Cell
Verified
Journal Article
Closed access
LCLaura Cato
Laura Cato
JTJonas de Tribolet-Hardy
Jonas de Tribolet-Hardy
ILIrene Lee
Irene Lee
JRJaice T. Rottenberg
Jaice T. Rottenberg
ICIlsa Coleman
Ilsa Coleman
MBMyles Brown
Myles Brown

30 September 2022 in Science Immunology
Verified
Journal Article
Open access
AMAnna Z. Mykytyn
Anna Z. Mykytyn
MRMelanie Rissmann
Melanie Rissmann
AKAdinda Kok
Adinda Kok
MRMiruna E. Rosu
Miruna E. Rosu
DSDebby Schipper
Debby Schipper
BHBart Haagmans
Bart Haagmans
The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy substantially. The Omicron variant termed BA.2, which differs substantially from BA.1 based on genetic sequence, is currently replacing BA.1 in several countries, but its antigenic characteristics have not yet been assessed. Here, we used antigenic cartography to quantify and visualize antigenic differences between early SARS-CoV-2 variants (614G, Alpha, Beta, Gamma, Zeta, Delta, and Mu) using hamster antisera obtained after primary infection. We first verified that the choice of the cell line for the neutralization assay did not affect the topology of the map substantially. Antigenic maps generated using pseudo-typed SARS-CoV-2 on the widely used VeroE6 cell line and the human airway cell line Calu-3 generated similar maps. Maps made using authentic SARS-CoV-2 on Calu-3 cells also closely resembled those generated with pseudo-typed viruses. The antigenic maps revealed a central cluster of SARS-CoV-2 variants, which grouped on the basis of mutual spike mutations. Whereas these early variants are antigenically similar, clustering relatively close to each other in antigenic space, Omicron BA.1 and BA.2 have evolved as two distinct antigenic outliers. Our data show that BA.1 and BA.2 both escape vaccine-induced antibody responses as a result of different antigenic characteristics. Thus, antigenic cartography could be used to assess antigenic properties of future SARS-CoV-2 variants of concern that emerge and to decide on the composition of novel spike-based (booster) vaccines.